Four hundred and fifteen (n = 415) patients with advanced or metastasised NSCLC receiving PD-1/PD-L1 inhibitors as the standard of care of the Network Oncology registry were enrolled. This evidence concerns the gene CD274 and non-small cell lung carcinoma.